Should I buy or sell Olema Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares. View OLMA analyst ratings or view top-rated stocks .

What is Olema Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Olema Pharmaceuticals' stock. Their OLMA share price targets range from $18.00 to $28.00. On average, they expect the company's share price to reach $21.43 in the next year. This suggests a possible upside of 115.8% from the stock's current price. View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts .

How have OLMA shares performed in 2024?

Olema Pharmaceuticals' stock was trading at $14.03 at the start of the year. Since then, OLMA shares have decreased by 29.2% and is now trading at $9.93. View the best growth stocks for 2024 here .

Are investors shorting Olema Pharmaceuticals?

Olema Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,100,000 shares, an increase of 60.1% from the March 15th total of 5,060,000 shares. Based on an average daily volume of 822,200 shares, the short-interest ratio is currently 9.9 days. View Olema Pharmaceuticals' Short Interest .

When is Olema Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OLMA earnings forecast .

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Monday, March, 11th. The company reported ($0.49) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.49).

When did Olema Pharmaceuticals IPO?

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free OLMA Stock Alerts

$9.93

+0.03 (+0.30%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.35
▼
$10.16
50-Day Range: $9.90
▼
$16.62
52-Week Range: $3.85
▼
$17.79

Volume: 744,438 shs
Average Volume: 787,540 shs
Market Capitalization: $555.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.43

Get Olema Pharmaceuticals alerts:

Olema Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 115.8% Upside
$21.43 Price Target
Short Interest: Bearish
14.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 2 Articles This Week
Insider Trading: Selling Shares
$835,400 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.34) to ($2.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

555th out of 911 stocks

Pharmaceutical Preparations Industry

246th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Olema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Olema Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.48% of the outstanding shares of Olema Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Olema Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.
Change versus previous month
Short interest in Olema Pharmaceuticals has recently increased by 60.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Olema Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Olema Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OLMA.

2.1

News and Social Media Coverage

News Sentiment
Olema Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Olema Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 12 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $835,400.00 in company stock.
Percentage Held by Insiders
23.50% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.34) to ($2.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Olema Pharmaceuticals is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Olema Pharmaceuticals is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Olema Pharmaceuticals has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

Click here and I’ll give you all the details.

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

OLMA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OLMA Stock News Headlines

March 30, 2024 | insidertrades.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $219,400.00 in Stock

April 16, 2024 | americanbankingnews.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Buy" from Analysts

April 20, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

April 12, 2024 | markets.businessinsider.com

Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge

April 10, 2024 | bizjournals.com

How Olema Oncology moved from layoffs to pivotal cancer drug studies

April 8, 2024 | globenewswire.com

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

April 2, 2024 | globenewswire.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024 | seekingalpha.com

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

April 20, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

March 16, 2024 | finance.yahoo.com

OLMA Jul 2024 12.500 call

March 16, 2024 | finance.yahoo.com

OLMA Apr 2024 22.500 call

March 15, 2024 | ca.finance.yahoo.com

OLMA Oct 2024 25.000 call

March 15, 2024 | ca.finance.yahoo.com

OLMA Oct 2024 10.000 put

March 13, 2024 | msn.com

3 Best Stocks to Buy Now, 3/13/2024, According to Top Analysts

March 12, 2024 | markets.businessinsider.com

Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity

March 12, 2024 | markets.businessinsider.com

Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment

March 12, 2024 | markets.businessinsider.com

Strong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ Palazestrant

March 11, 2024 | globenewswire.com

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

March 6, 2024 | markets.businessinsider.com

Buy Rating for Olema Pharmaceuticals’ Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer Treatment

March 6, 2024 | finance.yahoo.com

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

March 6, 2024 | globenewswire.com

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

March 4, 2024 | globenewswire.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 4, 2024 | finance.yahoo.com

Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

February 29, 2024 | msn.com

Olema Pharmaceuticals (NASDAQ:OLMA) Stock: Is There More Upside After a Remarkable Run in 2023?

February 17, 2024 | finance.yahoo.com

OLMA Mar 2024 20.000 call

February 17, 2024 | finance.yahoo.com

OLMA Mar 2024 10.000 put

January 8, 2024 | finance.yahoo.com

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

See More Headlines

Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OLMA
CUSIP: N/A
CIK: 1750284
Web: www.olema.com
Phone: 650-243-5555
Fax: N/A
Employees: 74
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.43
High Stock Price Target: $28.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +115.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,650,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -44.67%
Return on Assets: -40.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.33
Quick Ratio: 12.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.61 per share
Price / Book: 2.15

Miscellaneous

Outstanding Shares: 55,920,000
Free Float: 42,775,000
Market Cap: $555.29 million
Optionable: Optionable
Beta: 2.10

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Sean P. Bohen M.D. (Age 57)
Ph.D., President, CEO & Director
Comp: $1M
Mr. Shane William Charles Kovacs M.B.A. (Age 50)
Chief Operating & Financial Officer
Comp: $726.17k
Dr. Naseem Zojwalla M.D. (Age 51)
Chief Medical Officer
Comp: $775.48k
Mr. Geoffrey Mogilner
Vice President of Investor Relations & Communications
Ms. Julie Dexter
Senior VP & Head of People
Dr. David C. Myles Ph.D. (Age 61)
Chief Discovery & Non-Clinical Development Officer
Comp: $200k
Ms. Demiana Faltaos Ph.D.
Pharm.D., VP & Head of Clinical Pharmacology
Mr. John B. Moriarty Jr. (Age 56)
J.D., Corporate Secretary
Comp: $434.32k
Ms. Sasha Austin CPA
VP of Finance & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OLMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Olema Pharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OLMA shares.
View OLMA analyst ratings or view top-rated stocks.
What is Olema Pharmaceuticals' stock price target for 2024?: 8 equities research analysts have issued 12-month price targets for Olema Pharmaceuticals' stock. Their OLMA share price targets range from $18.00 to $28.00. On average, they expect the company's share price to reach $21.43 in the next year. This suggests a possible upside of 115.8% from the stock's current price.
View analysts price targets for OLMA or view top-rated stocks among Wall Street analysts.
How have OLMA shares performed in 2024?: Olema Pharmaceuticals' stock was trading at $14.03 at the start of the year. Since then, OLMA shares have decreased by 29.2% and is now trading at $9.93.
View the best growth stocks for 2024 here.
Are investors shorting Olema Pharmaceuticals?: Olema Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,100,000 shares, an increase of 60.1% from the March 15th total of 5,060,000 shares. Based on an average daily volume of 822,200 shares, the short-interest ratio is currently 9.9 days.
View Olema Pharmaceuticals' Short Interest.

When is Olema Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our OLMA earnings forecast.
How were Olema Pharmaceuticals' earnings last quarter?: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its earnings results on Monday, March, 11th. The company reported ($0.49) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.49).
When did Olema Pharmaceuticals IPO?: Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.
How do I buy shares of Olema Pharmaceuticals?: Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OLMA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Olema Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

OLMA Stock Price History

OLMA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OLMA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™